Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Danielle Pillsbury2025 年 3 月 20 日
Gene Therapy: A Transformative Shift in Rare Disease Treatment Video Gene Therapy: A Transformative Shift in Rare Disease Treatment After decades of promise, gene therapy is finally starting to deliver on its potential—especially for…Danielle Pillsbury2025 年 2 月 26 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication 针对复发难治性(R/R)骨髓纤维化(MF)及其他髓系或实体瘤恶性肿瘤患者的 Navtemadlin 群体药代动力学与药效学分析 This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…Danielle Pillsbury2025 年 2 月 6 日
Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters Blog 为何 FDA 批准 omaveloxolone 用于治疗弗里德赖希共济失调症意义重大 2025 年 1 月 10 日 Friedreich’s Ataxia (FA) is a rare, genetic, and progressive neurodegenerative disorder. A…Danielle Pillsbury2025 年 1 月 10 日
Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster 临床前数据暴露无法预测双特异性 T 细胞吸引剂在实体瘤适应症中的临床生理活性剂量;是否有更好的衡量标准?— 来自小型机制性 MBMA 的启示 Danielle Pillsbury2024 年 12 月 11 日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Poster 复发/难治性多发性骨髓瘤患者 Belantamab Mafodotin、可溶性B细胞成熟抗原(BCMA)和血清 M-蛋白的群体药代动力学-药效学(PKPD)同步分析 Danielle Pillsbury2024 年 11 月 22 日
A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Poster 利用新型深度学习模型进行药物浓度的药代动力学分析 Danielle Pillsbury2024 年 11 月 22 日
Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies Poster 用于开发和优化靶向辐射疗法剂量的模型引导的药物开发框架 Danielle Pillsbury2024 年 11 月 22 日
Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials Poster 肿瘤学 MIDD 模拟器 — 用于早期肿瘤学试验总生存期预测的用户友好型应用程序 Danielle Pillsbury2024 年 11 月 22 日
Population pharmacokinetic modeling of niraparib to assess different absorption models Poster 尼拉帕利(Niraparib)群体药代动力学建模以评估不同吸收模型 Danielle Pillsbury2024 年 11 月 22 日